10 - 11 December 2018, London, UK.
The 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies, from biotech’s to pharma, need to adapt, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry.

17 - 18 October, London, UK.
Patients with rare diseases cannot continue to be overlooked because of costly therapies and have the same rights to treatment as any other patient. At this year's Orphan Drugs and Rare Diseases conference, organised by SMi Group and taking place in London, industry experts will address the opportunities and challenges within the rare disease treatment field.

26 - 27 September, London, UK.
Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.

26 - 27 November 2018, London, UK.
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.

10 - 11 October, London, UK.
SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018, with an interactive pre-conference workshop on the 9th October. Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.

26 - 27 September 2018, London, UK.
The SMi Group are thrilled to present the 9th annual conference on Biosimilars & Biobetters, taking place on 26th & 27th September in Central London, UK. Following the success of the previous events in both London and the US, Biosimilars and Biobetters UK 2018 will deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.

9 - 10 July 2018, London, UK.
Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.